# A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

> **NCT04740671** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 410 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** HLX04-O
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT04740671
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740671, "A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04740671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*